plays a central role in the development of its mutagenicity and clastogenicity, and further that inhibition of CYP2E1 by diallyl sulfone (DASO 2 ) leads to diminution in their incidences.
Vinyl carbamate (VC) is a metabolite of ethyl carbamate, a naturally-occurring compound found in fermented foods and alcoholic beverages. CYP2E1 mediates the sequential oxidation of ethyl carbamate to VC and subsequently to the VC epoxide, which is believed to be the ultimate carcinogenic species. Here, we have tested the hypothesis that bioactivation of VC by CYP2E1 plays a central role in the development of its mutagenicity and clastogenicity, and further that inhibition of CYP2E1 by diallyl sulfone (DASO 2 ) leads to diminution in their incidences. DASO 2 is a garlic constituent that is oxidized by CYP2E1, leading to inactivation of this P450. 
Introduction
Vinyl carbamate (VC) is derived from oxidative metabolism of ethyl carbamate (EC), a compound used historically as a cosolvent with analgesic and sedative drugs (1) , as well as an anti-neoplastic agent for treatment of chronic leukemia and multiple myeloma (2) . EC is formed in fermentation of alcoholic beverages and food products including bread, cheese, yogurt, soya sauce and vinegar (3) (4) (5) . The amounts of EC found in various food items included the following:
stone-fruit brandies (2000 ng/g), table wines (10-15 ng/g), sake rice wine (130 ng/g), bread (7 ng/g), yogurt (< 1 ng/g) and soy sauce (18 ng/g) (5) . Hence, human exposure occurs inadvertently via consumption of alcoholic beverages and fermented foods. The mean daily intake of EC from various food items in adults has been estimated to be about 10-20 ng/kg of body weight (5) . EC has been identified as a carcinogen in species including mice, rats, hamsters and monkeys (6) (7) (8) , and has been classified as a possible human carcinogen by the
International Agency for Research on Cancer (2).
First reported to produce adenomas in the lungs of mice (9) , EC was subsequently shown to initiate tumors in a variety of tissues including the skin, liver, mammary gland and lymphoid tissue (10, 11) . However, lung tumors induced by EC are manifested in 2 to 6 months, whereas tumors in other tissues required a latent period of about a year (6, 12) . Although a similar spectrum of tumors is induced by both EC and VC, VC is a more potent carcinogen than EC, producing lung tumors that are 20-to 50-fold greater in number than are induced by EC at similar doses (13, 14) . Moreover, in comparison with EC, VC induces 3-fold higher levels of DNA adducts in liver and lung (15) , has 40 times the clastogenic potency of EC, and induces a higher frequency of micronucleated reticulocytes in peripheral blood (16) . Recent in vivo studies, using F 1 (Big Blue ® x A/J) transgenic mice and phage cII as a reporter gene, demonstrated that a dose of EC that was 17-fold greater was required to produce similar MF values in the lung as was induced by VC (60 mg/kg, i.p.) (17) . These findings are consistent with data showing that VC is a more potent carcinogen than EC, and further that the lung is a highly susceptible target tissue.
Previous studies have postulated that the carcinogenicity of EC is mediated by its metabolism to VC and subsequently to VC epoxide (VCO), a metabolite that has been proposed to be the ultimate carcinogenic species (13, 14) . Subsequent studies, using human liver microsomes, provided data to support this early proposal, and implicated CYP2E1 in the sequential oxidation of EC to VC and ultimately to VCO (18, 19) . This bioactivation pathway involving CYP2E1 has also been identified in murine and human lung (20-22 (27) . The controls consisted of mice that were (i) treated with the vehicle (untreated), (ii) treated with DASO 2 alone, or (iii) treated with VC alone.
Sampling of tissues
The lungs were excised and rinsed in saline. The entire length of the small intestine was removed, flushed with phosphate buffered saline, and inverted using a thin metal probe.
Epithelial suspensions were made from the small intestine by placing the tissue in 3 ml of 75 mM KCl/20 mM EDTA solution and gently forcing it in and out of a 5 cc syringe without a needle. After isolation, all tissues were immediately frozen with liquid nitrogen and then stored at −80 °C.
DNA extraction
The tissues (lung and small intestine epithelial suspensions) were incubated overnight in lysis buffer (10 mM Tris pH 8, 150 mM NaCl, 20 mM EDTA), containing 125 μg/ml of proteinase K, 100 μg/ml RNase and 1% sodium dodecyl sulfate, in a water bath maintained at 55 °C.
Extraction of DNA was carried out by standard procedures using phenol/chloroform/ isoamyl alcohol (25:24:1) and chloroform and precipitated with 100% ethanol. The DNA was collected by spooling with a capillary tube with a hook at one end, and stored in 100 μl of Tris-EDTA buffer (10 mM Tris, 1 mM EDTA, pH 8) for 4 to 5 days at room temperature. The concentration of DNA was determined by measuring the optical density of the samples at 260 nm.
cII Mutation assay
The λLIZα shuttle vector containing the cII transgene was recovered by in vitro packaging using 
Micronucleus assay
The frequency of micronucleated peripheral blood reticulocytes was determined according to the method of Hayashi et al. (27) . Briefly, tail blood was obtained 48 h after VC treatment, which was identified previously as the time of manifestation of maximum frequencies of micronucleated reticulocytes (16) . A volume of 5 μl of tail blood was placed on a glass slide precoated with 10 μl of 1% acridine orange solution. A cover glass was placed over the blood sample and the blood cells left to stain for 3-15 h. One thousand reticulocytes from each animal were analyzed, using a fluorescence photomicroscope. The method by Hayashi et al. (27) uses acridine orange-coated slides to detect micronuclei in reticulocytes (young RNA-containing erythrocytes). In this assay, a fluorescence photomicroscope equipped with a blue excitation and a 515-530 nm barrier filter was used to distinguish between the micronuclei that fluoresce strongly green and the reticulum structure of reticulocytes that fluoresce red.
Statistical analysis
Data were expressed as mean ± SEM. Data of MFs were analyzed using the Mann-Whitney Utest. The program developed by Cariello et al. (28) was used to analyze differences between the mutation spectra of the various experimental groups. Differences between experimental groups in the micronucleus assay were determined by using one-way ANOVA and a Bonferroni adjustment. The level of significance for all data analyses was set at P < 0.05.
Results

Dose-response studies with DASO 2 in lung
All mice survived until the study was completed 4 weeks after the various treatments. Table I shows MF data in the lungs of individual male and female mice (refer also to Supporting Document). Since there were no differences in the MFs between male and female mice, the MF values were pooled and treated as a single group of mice. Spontaneous mutations were detected in control mice treated with neither DASO 2 nor VC, but the incidences and resultant MFs were low. Treatment of mice with VC alone produced a MF value that was 5-fold of the level in the untreated control (Table I ). The MF of mice treated with 12.5 mg/kg of DASO 2 and VC was significantly different from mice treated with DASO 2 alone, but did not differ significantly from mice treated with VC alone. Increase of the DASO 2 dose to 25 mg/kg resulted in a decrease in the MF in VC-treated mice. However, in view of the considerable variability in the data from individual mice in this experimental group, the MFs were not statistically different from mice treated with DASO 2 alone as well as from mice treated with VC alone (Table I) . Increase of the DASO 2 doses to 50 and 100 mg/kg followed by VC generated MFs that were significantly different from mice treated with the same doses of DASO 2 and from mice treated with VC alone.
Hence, the 50 mg/kg DASO 2 dose was regarded as the minimum dose that elicited a significant decrease in MFs. Treatment of mice with 200 mg/kg of DASO 2 and VC produced MF data that were similar to mice treated with the same dose of DASO 2 . These data demonstrated dosedependent decreases in VC-induced MFs in the lungs of mice pretreated with DASO 2 . However, only a MF value similar to that in untreated mice was manifested in mice treated with 200 mg/kg of DASO 2 and VC.
Dose-response studies with DASO 2 in small intestine
Details of MF values in the small intestine in individual mice are given in Table II (refer also to Supporting Document). As found in the lung, no differences in MF values were observed between male and female mice, and therefore the data were pooled and treated as a single group.
As found in the lung, the low MFs observed in control mice indicated that the incidence of spontaneous mutations in the small intestine was minimal. The MF in the small intestine of mice treated with only VC was a significant 3.3-fold higher than the untreated control (Table II) .
Treatment with 100 or 200 mg/kg of DASO 2 and VC elicited MFs that were significantly higher than mice treated with the same doses of only DASO 2 . However, treatment with 100 mg/kg of DASO 2 and VC produced a MF that was not significantly different from mice treated with VC alone. When mice were treated with 200 mg/kg of DASO 2 and VC, a significant decrease of 41% was observed, compared with the MF in mice treated with VC alone. Thus, it was only in the case of the 200 mg/kg DASO 2 dose that there was a significant reduction in VC-induced MF.
Comparisons of the MF data showed no significant differences in the MFs between the lung and small intestine (Tables I and II) . Table III transversions. The C to T transitions (6/6, 100%) in the DASO 2 /VC group all occurred at CpG sites. Statistical analysis, applying the program developed by Cariello et al. (28) , showed that the cII mutation spectra in the lungs of all the experimental groups were not statistically different from one another. Table IV transitions occurred at CpG sites. Statistical analysis revealed that, as found in the lung, the mutation spectra from the various experimental groups were not significantly different from one another. Thus, pretreatment with DASO 2 did not affect the mutation spectra induced by VC in the small intestine.
Sequencing
Micronucleus analysis
The frequency of micronucleated reticulocytes is considered as a valid index of in vivo clastogenicity. Details of the frequencies of micronucleated reticulocytes in peripheral blood are given in Table V . There was no significant difference in the frequencies of micronucleated reticulocytes between male and female mice, and therefore the values were pooled and treated as a single group. The frequencies of micronucleated reticulocytes in mice treated with DASO 2 at doses of 50 to 200 mg/kg remained similar to the levels found in untreated control mice (Table   V) . Compared to the frequency of micronucleated reticulocytes in control mice, treatment with VC (60 mg/kg, i.p.) elicited a significant 6.8-fold increase in the frequency 48 h after treatment.
There was no significant difference in the frequencies of micronucleated reticulocytes between untreated mice and mice treated with DASO 2 (50 mg/kg, p.o.) The frequencies following treatment with DASO 2 and VC were both 4.5-fold higher than those in untreated mice and mice treated with DASO 2 . However, the frequency in mice treated with DASO 2 and VC were a significant 33% less than in VC-treated mice. Increase of the treatment doses of DASO 2 to 100 or 200 mg/kg did not augment its inhibitory effects on micronuclei formation; the frequencies of micronucleated reticulocytes remained similar to the level found in mice treated with 50 mg/kg DASO 2 (Table V) .
Discussion
Recent studies have produced evidence to support the involvement of CYP2E1 in VC oxidation (29) . Incubation of VC with recombinant CYP2E1 resulted in the generation of VCO, a putative reactive species that reacted with 2′-deoxyadenosine to produce the adduct, 1, In view of the finding that, in addition to CYP2E1, DASO 2 also inhibits the CYP2F enzyme (23), it was relevant to determine whether this P450 was implicated in εdAS formation. Preliminary studies confirmed that εdAS was not detected in incubations of VC with recombinant mouse CYP2F2 or recombinant rat CYP2F4 (29) . Hence, the inhibitory effect of DASO 2 on εdAS production is mediated mainly by CYP2E1, and is ascribed to generation of an epoxide from DASO 2 , resulting in formation of the heme adduct, N-alkylprotoporphyrin IX, and CYP2E1
inactivation (33, 34) . In view of the metabolic events induced by VC and the inhibition of εdAS formation by DASO 2 as well as the link between εdAS formation and development of mutations, we postulated that pretreatment of mice with DASO 2 will lead to inhibition of the frequencies of mutations and micronucleated reticulocytes.
Proclivities for development of lung tumors differ in various inbred strains of mice. Strain
A/J mice are susceptible, whereas C57BL/6 mice are resistant to lung tumor formation (12, 35 ).
This marked difference in susceptibility is associated with enhanced capacities for VC bioactivation in the lungs of the susceptible A/J vs. resistant C57BL/6 mice. In comparison with C57BL/6 mice, A/J mice had elevated levels of CYP2E1, exhibited increased covalent binding of VC to lung proteins, and generated 70% higher levels of εdAS and 3,N 4 -ethenodeoxycytidine from VC (36) . Here, we have crossed Big Blue ® mice with a C57BL/6 background with Strain A/J mice, and used the hybrid offspring in our studies. This hybrid strain has been reported to possess intermediate susceptibility in lung tumor development (37) . The λ cII positive selection system detects mutations in the λ cII transgene gene, and is embedded in multiple copies in all tissues of Big Blue ® mice (25), thus allowing for mutational comparisons between various tissues in the same animal. After DNA extraction, the cII transgene is recovered by packaging the DNA into phage and infecting an hfl -strain (E. coli G1250). Only phage with cII mutations in the λ cII transgene lyse and form plaques at low temperatures (24ºC), while all infected bacteria lyse and form plaques at 37ºC. Mutant frequency is assessed by calculating the ratio of mutant plaques to the total bacterial cells that were infected, and this ratio is considered a valid index for in vivo mutagenicity. The mutant plaques can be cored and sequenced for the identification of mutations induced by the test compound in the λ cII transgene (25). In this study, the λ cII mutation assay was used to determine the incidences of mutations in the lung and small intestine in which is the minimum amount of time required for the MF to reach a plateau (17) . Although the manifestation time in intestinal epithelium has been reported to be one week or less (38) , our studies have nonetheless demonstrated dose-dependent formation of mutations from VC at 4 weeks. Hence, VC was found to be as equally mutagenic in the lung as in the small intestine after 4 weeks of treatment at doses of 45, 60 and 75 mg/kg (17) and thus, both tissues were assayed after 4 weeks.
In this study, treatment of mice with VC alone produced a MF in the lung that was 5-fold of the incidence of spontaneous mutations in mice given neither DASO 2 nor VC, attesting to the highly mutagenic potential of VC (Table I) . Pretreatment of mice with DASO 2 alone did not alter the MF, and hence DASO 2 has no mutagenic effect in the lung. However, pretreatment with DASO 2 elicited dose-dependent decreases in VC-induced MF. A 50% decrease in MFs was detected in the lungs of mice pretreated with DASO 2 doses of 25 to 100 mg/kg, while a 70% decrease was detected upon pretreatment with a dose of 200 mg/kg (Table I ). In the small intestine, the MF generated by VC after pretreatment with 100 mg/kg of DASO 2 was similar to the MF induced by treatment with VC alone (Table II) . However, when DASO 2 pretreatment was carried out with a dose of 200 mg/kg, the MF was significantly reduced, compared to the MF induced by VC alone. These findings demonstrated that DASO 2 exerted an inhibitory effect on the formation of mutations that was more pronounced in the lung than in the small intestine.
A DASO 2 dose of 25 mg/kg produced a 50% decrease in MF in the lung, while a dose of 200 mg/kg produced a 41% decrease in MF in the small intestine. This discrepancy in MF values between the lung and the small intestine may be attributed to the differing levels of CYP2E1 present in the two tissues. In contrast to the lung in which CYP2E1 is a major P450 (39, 40) , CYP2E1 is present at low levels in the small intestine (41) . Immunoblot analysis of the entire small intestine showed low levels of the CYP2E1 protein, which is consistent with a weak CYP2E1 signal from total RNA from small intestinal enterocytes (41) . It should be noted, however, that published data regarding the expression of intestinal P450 enzymes are variable, and may be due, in part, to difficulties in microsomal preparation as a result of high levels of proteases in this tissue (42). Despite the low CYP2E1 expression in the small intestine, the MF (8.7 ± 1.3) in this tissue in VC-treated mice was similar to that in the lung (11.4 ± 2.2),
suggesting that P450 enzymes other than CYP2E1 might be involved. However, it should be noted that, to the best of our knowledge, the P450-dependent bioactivation of VC and the (Tables III and IV) . Similar mutations were also generated in mice treated with VC in conjunction with DASO 2 : (i) G:C to A:T transitions (lung = 21%; small intestine = 25%) (ii) A:T to G:C transitions (lung = 25%; small intestine = 31%) and (iii) A:T to T:A transversions (lung = 30%; small intestine = 21%).
Statistical analysis confirmed that the mutation spectra produced by VC in the lung did not differ from those in the small intestine. Moreover, the mutation spectra found in the lung and small intestine of mice treated with DASO 2 alone did not differ from the controls, suggesting that DASO 2 did not affect the distribution of the mutations. In addition, the mutation spectra induced by VC did not differ from those generated in the lung and small intestine when the mice were pretreated with DASO 2 . These findings demonstrated that DASO 2 pretreatment does not alter the mutation spectra induced by VC in both the lung and small intestine. The effects of VC are associated with not only mutagenic but also clastogenic events. VC has also been shown to induce a high frequency of micronucleated reticulocytes in male B6C3F1 mice (16) . In this study, the results demonstrated that VC induced a high frequency of micronucleated reticulocytes, and further that pretreatment with DASO 2 (50 mg/kg) significantly reduced (33%) the incidence of micronucleated reticulocytes (Table V) . Treatment with increased doses of DASO 2 (100 or 200 mg/kg) elicited no additional inhibitory effects on the incidence of micronucleated reticulocytes produced by VC. These results suggested that the inhibition evoked by the 50 mg/kg dose of DASO 2 was the maximum achievable for micronuclei formation.
In summary, our results demonstrated that pretreatment of mice with DASO 2 significantly decreased VC-induced MFs in the lung and small intestine, but did not alter the mutation spectra in either tissue. Pretreatment with DASO 2 also significantly decreased the frequency of micronucleated reticulocytes produced by VC. These findings showed that DASO 2 has antimutagenic properties in the lung and small intestine, and anti-clastogenic properties in peripheral reticulocytes. Importantly, these results affirmed that VC bioactivation plays a central role in b Significantly different from the untreated control or the groups treated with DASO 2 alone (P < 0.05).
c Significantly different from mice treated with VC alone or mice treated with 12.5 mg/kg of DASO 2 and VC (P < 0.05 or d P < 0.01). b Significantly different from their respective control groups (P < 0.01).
c Significantly different from mice treated with VC alone or mice treated with 100 mg/kg of DASO 2 followed by VC treatment 2 h later (P < 0.05). (14) 10 (14) 9 (12) Mutants refer to the total number of mutants sequenced in each treatment group. b Mutations refer to the number of independent mutations adjusted for clonal expansion (the same mutation in more than one mutant plaque in the same mouse). and VC (P < 0.05 or † † P < 0.01). followed by VC treatment 2 h later (P < 0.05).
